<DOC>
	<DOC>NCT02646267</DOC>
	<brief_summary>The purpose of this trial is to demonstrate the efficacy and safety of dabigatran etexilate and different intensity warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.</brief_summary>
	<brief_title>The Efficacy and Safety Study of Dabigatran and Warfarin to Non-valvular Atrial Fibrillation Patients</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>1. Clinical diagnosis of atrial fibrillation 2. Echocardiography confirmed a nonvalvular heart disease 3. Ageâ‰¥60 years 1. Unable to cooperate with doctors 2. CHA2DS2VASc&lt;2 3. Life expectancy of less than 1 year 4. Rheumatic heart disease or dilated cardiomyopathy 5. History of artificial valve replacement surgery 6. Infectious endocarditis 7. Stroke or transient ischemic attack(TIA) within the last 6 months 8. Previous history of intracranial hemorrhage, gastrointestinal, respiratory or urogenital bleeding 9. Previous intolerance/allergy to warfarin or dabigatran etexilate 10. Blood pressure greater than 180/110 mmHg 11. Chronic liver dysfunction, alanine aminotransferase above the normal reference value of the upper limit 3 times 12. Chronic renal failure, serum creatinine clearance rate (Ccr) less than 30 ml / min 13. Patient was receiving antiplatelet or anticoagulant therapy due to other reasons</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Atrial fibrillation</keyword>
	<keyword>Dabigatran</keyword>
	<keyword>Warfarin</keyword>
	<keyword>Anticoagulation</keyword>
	<keyword>Elderly</keyword>
</DOC>